News
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced today new data from the real-world evidence clinical study called “POSITIVE” demonstrating that Ilumetri®
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug
Almirall’s Nine-month 2023 Results:
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
Financial highlights (€ rounded million)
9M 2023
9M 2022
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
43rd Annual Fall Clinical Dermatology Conference
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
Financial highlights (€ rounded million)
H1 2023
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “Capital Increase”) for
Almirall’s First Quarter 2023 Results
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
Financial highlights (€ rounded million)
Q1 2023
Almirall’s Full-Year 2022 Results
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
Financial highlights (€ rounded million)
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San
Almirall’s Nine-month 2022 Results
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.
Financial highlights (€ rounded million)
9M 2022
It’s Time to Rotate Into These Russell 2000 Stocks
The Russell 2000 (INDEXRUSSELL: RUT) has lagged the broad market for years because its small-cap names carry larger-than-average risk in economically constrained environments. Economic constraints
Evolv Technologies Had a Bad Week, Is it Time to Buy or Fade?
A bad week continues to get worse for Evolv Technologies Holdings Inc. (NASDAQ: EVLV). The AI-based weapons detection company's stock was subject to a limit up, limit down (LULD) pause after
Lake Victoria Gold: Entscheidender Schritt auf dem Weg zur Goldproduktion
Zweite Investitionstranche der TAIFA Group wird ausgelöst
Lake Victoria Gold (TSX-V:LVG; FRA: E1K) hat eine formal entscheidende Hürde beim Erwerb des fortgeschrittenen Imwelo Goldprojekts
